TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of diffuse large B cell Non-Hodgkin's lymphoma with characteristic immunophenotypic profile~* Patient has not received any prior anti-cancer therapy for lymphoma~* Tumor tissue confirmed to express the cluster of differentiation antigen 20 antigen by flow cytometry or immunohistochemistry~* Measurable disease as defined by a tumor mass of 1cm or greater in one dimension~* Stage II (abdominal-not radiotherapy appropriate), III, or IV disease~* Age \> 18 years~* Performance Status of 0-2~* Laboratory parameters as outlined in protocol~* Patient agrees to use birth control~Exclusion Criteria:~* Known central nervous system involvement by lymphoma~* Serious uncontrolled concurrent illness such as active coronary artery disease, severe lung disease, heart failure, active alcohol abuse, active concurrent malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix~* Any evidence of prior natural exposure to Hepatitis B~* Active rheumatologic disease which may be exacerbated by GM-CSF~* Cardiac ejection fraction less than 45%~* Known HIV disease~* Patient is pregnant or nursing~* Patient is receiving other investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GMCSF-RCHOP (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Blood Sparing Strategies: Omni-stat Routinary Use in Cardiac Surgery. A Prospective Randomized Study.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients undergoing heart surgery~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control (Type: ACTIVE_COMPARATOR): Traditional best-practice surgical hemostasis
- Omni-stat Celox (Type: EXPERIMENTAL): Administration of 6 gr of Omni-stat Celox intraoperatively at the time of Hemostasis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cardiac Resynchronization Under Electroanatomical Guidance After Failure of Primary Implantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patient with indication for implantation of a classic multisite pacemaker;~* New York Heart Association II/IV patient despite optimal medical treatment;~* Patient with left ventricular ejection fraction ≤35%;~* Patient with a widened QRS \> 120ms;~* Patient with at least one lateral coronary sinus vein visualized on angiography during the 1st procedure (if performed);~* Patient with failure of resynchronization via the endovenous route due to difficulty in accessing the coronary sinus or instability in the coronary sinus;~* Patient having been informed and having signed an informed consent form;~* Patient able to understand the information related to the study (absence of linguistic, psychological, cognitive problem, etc.), and to complete questionnaires.~Exclusion Criteria:~* Patient with resynchronization failure due to occlusion of the superior vena cava;~* Patient with no usable lateral coronary sinus vein;~* Patient with a life expectancy \< 3 months;~* Patient wearing a vena cava filter;~* Patient with active sepsis;~* Pregnant or likely to be pregnant (of childbearing age, without effective contraception) or breastfeeding;~* Patient participating in another clinical trial, or in a period of exclusion from another clinical trial;~* Patient not benefiting from a social security scheme.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3-dimensional guidance technique (Type: EXPERIMENTAL): 3-dimensional (3D) guidance technique to position the heart probes in the setting up of a pace maker

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Sign informed consent~* Subjects who present for Liver Transplantation~* Subjects who present for Hepatic resection~* Subjects with Non-Surgical Liver Disease~Exclusion Criteria:~* Absence of Liver Disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): 50 surgical subjects undergoing either liver transplantation or hepatic resection
- 2 (Type: OTHER): 50 Subjects with Liver disease who are are not surgical candidates

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Histologically confirmed Stage III-IV epithelial ovarian, fallopian tube, or primary peritoneal cancer, including malignant mixed Müllerian tumors with high grade serous component~* Patients must be candidates for platinum based chemotherapy and previously untreated~* Patients must have completed a surgical debulking procedure, or be candidates for neoadjuvant chemotherapy~* Availability of an archival formalin fixed, paraffin embedded (FFPE) tumor tissue block or a minimum of 15 slides~* ECOG PS 0-1~* Adequate hematological, renal, and liver function~Key Exclusion Criteria:~* Non epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors~* Prior systemic anti-cancer treatment for EOC, FTC, or PPC including prior immunotherapy with IL 2, IFN α, or anti PD 1, anti PD L1, anti PD L2, anti CD137, or anti cytotoxic T lymphocyte associated antigen 4 (anti CTLA 4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T cell co stimulation or immune checkpoint pathways~* Patients for whom, in the opinion of the Investigator, there is clinical benefit to administer bevacizumab as a first-line treatment and for whom bevacizumab is approved and available in this setting.~* Cancer for which intraperitoneal cytotoxic chemotherapy is planned~* Active autoimmune disease (some exceptions include diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroidism not requiring immunosuppressive treatment)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A (Type: ACTIVE_COMPARATOR): Chemotherapy followed by observation
- Arm B (Type: EXPERIMENTAL): Chemotherapy followed by avelumab in maintenance
- Arm C (Type: EXPERIMENTAL): Chemotherapy in combination with avelumab followed by avelumab in maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Obeticholic Acid in Patients With Moderately Severe Alcoholic Hepatitis (AH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Individuals ≥ 21 years with a diagnosis of acute AH. The diagnosis of acute alcoholic hepatitis will be based on clinical features and testing including hepatomegaly, jaundice, fever, leukocytosis, compatible liver biochemistries in the context of heavy alcohol consumption. A liver biopsy is not mandatory, but will be required to confirm the diagnosis if a firm diagnosis of AH cannot be made on clinical and laboratory criteria~* Moderate severity defined as MELD score \> 11 and \< 20~* Heavy alcohol consumption (defined as \> 40 grams per day on average in women and \> 60 grams per day on average in men for a minimum of 6 months and within the 6 weeks prior to study enrollment)~* Written informed consent~* Negative urine pregnancy test where appropriate~* Women of child bearing potential should be willing to practice contraception throughout the treatment period~Exclusion Criteria:~* Significant active infection (e.g., sepsis, or spontaneous bacterial peritonitis; SBP). Subjects can be reconsidered after the infection is under control.~* Serum creatinine \> 2.5 mg/dL~* Must not be receiving systemic steroids \> 1 week at the time of Screening or any experimental medicines for AH~* Presence of any other disease or condition that is interfering with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the intestine. Patients who have undergone gastric bypass procedures will be excluded (gastric lap band is acceptable).~* Participation in another investigational drug, biologic, or medical device trial within 30 days prior to screening

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo
- 10 mg Obeticholic Acid (OCA) (Type: EXPERIMENTAL): 10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily for 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Acupuncture in Treating Nerve Pain in Patients With Stage I, Stage II, or Stage III Breast Cancer Who Are Receiving Paclitaxel

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion~* Patients must have a history of histologically or cytologically confirmed stage I, II, or III breast cancer that have received 2 cycles of paclitaxel, and expected to receive paclitaxel for two more cycles, and are experiencing grade 1 peripheral neuropathy (CTCAE criteria)~* Performance ECOG 0-2 (Karnofsky Performance Status \>= 60%)~* Life expectancy of greater than 6 months~* Ability to understand and the willingness to sign a written informed consent document~Exclusion~* Patients with radiologically confirmed stage IV breast cancer~* Patients who had acupuncture in the previous 8 weeks~* Change in use of any of the following drugs in the prior 4 weeks: opiates, antidepressants, or anxiolytics (change is defined as initiation or cessation of treatment, or change in prescribed dose or regimen)~* Patients with needle phobia~* Patients who experienced any peripheral neuropathy prior to chemotherapy~* Patients who have the potential for serious bleeding due to inherited diseases such as hemophilia~* Patients with diabetes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks during courses 3 and 4.
- Arm II (Type: EXPERIMENTAL): Patients receive paclitaxel as standard of care every 2 weeks for 4 courses. Patients then undergo acupuncture therapy comprising 2 30-minute sessions a week for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Standard Bupivacaine vs Liposomal Bupivacaine in Colorectal Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Undergoing elective colectomy by surgeons of Fairfax Colon and Rectal Surgery~Exclusion Criteria:~* Allergic to local anesthetics~* Unable to provide consent~* Pregnant~* On opioids at home chronically (Patients previously on a regular opioid regimen would need to be opioid-free for a period of 1 year for inclusion in the study)~* Undergoing emergent operations~* Undergoing loop ileostomy reversal~* Undergoing abdominoperineal resection, pelvic exenteration, or perineal rectal prolapse repairs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Bupivacaine (Type: ACTIVE_COMPARATOR): Standard (0.25% bupivacaine) bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.
- Bupivacaine Liposome (Type: EXPERIMENTAL): Liposomal bupivacaine (133 mg in 10mL, diluted with 20 mL saline) will be injected into the fascial layer between the internal oblique and the transversus abdominis with ultrasound guidance, 30 mL per side for a total of 60 mL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven completely resected stage III or IV cutaneous, mucosal, or ocular melanoma Disease free, but at high risk of relapse Must meet 1 of the following criteria: Failed interferon alfa (IFN-A) therapy Ineligible for IFN-A therapy Refused IFN-A therapy HLA-A2.1 positive Availability of tumor tissue for analysis of gp100 antigen staining with antibody HMB-45, and for expression of tyrosinase and MART-1 antigens by immunohistochemistry Tumor cells must be positive for at least 1 antigen~PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0 or 1 Life expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Granulocyte count at least 1,500/mm3 Hemoglobin at least 9.0 g/dL Platelet count at least 100,000/mm3 No coagulation or bleeding disorders Hepatic: Bilirubin no greater than 2.0 mg/dL SGOT and SGPT no greater than 2.5 times upper limit of normal Renal: Creatinine no greater than 2.0 mg/dL Cardiovascular: No concurrent major medical illness of the cardiovascular system Pulmonary: No concurrent major medical illness of the respiratory system Immunologic: Hepatitis B surface antigen negative and hepatitis C antibody negative HIV negative No history of uveitis or other autoimmune inflammatory eye disease No other active autoimmune disease No known allergic reaction to Montanide ISA-51 Other: No concurrent major systemic infection including pneumonia or sepsis No concurrent major medical illness of the gastrointestinal system Not pregnant or nursing Negative pregnancy test No other malignancy within the past 5 years except curatively treated squamous cell skin cancer or carcinoma in situ of the cervix allowed 30 days after treatment~PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No prior tyrosinase:368-376 peptide, gp100:209-217 antigen, or MART-1:26-35 antigen Chemotherapy: Not specified Endocrine therapy: No concurrent steroids Radiotherapy: At least 1 month since prior radiotherapy No concurrent radiotherapy Surgery: See Disease Characteristics Other: At least 1 month since other prior therapy, including adjuvant therapy, for melanoma No other concurrent anticancer therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Is Procardia XL 60 mg Q Daily Equivalent to 30 mg XL Given Twice Daily?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Antepartum or postpartum patients between the age of 18-55 requiring 60 mg of Procardia XL to control elevated blood pressures secondary to preeclampsia, gestational hypertension, or chronic hypertension.~Exclusion Criteria:~* All patients receiving other antihypertensive medication~* All patients with a contraindication to nifedipine: Hypersensitivity to nifedipine or other calcium -channel blocker, cardiogenic shock, concomitant administration with strong CYP34A inducers (rifampin, rifabutin, phenobarbital, phenytoin, carbamazepine, St Johns Wort) → significantly reduces nifedipine efficacy, impaired liver function→? Patients with hepatic impairment (liver cirrhosis) have a longer disposition half-life and higher bioavailability of nifedipine than healthy volunteers~* Patients over the age of 55

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Procardia XL 30 mg (Type: EXPERIMENTAL): Procardia XL 30 mg XL Q 12h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia XL divided in 2 doses of 30 mg given 12h apart.
- Procardia XL 60 mg (Type: ACTIVE_COMPARATOR): Procardia XL 60 mg Q 24h - When a patient's BP is persistently elevated after a dose of 30 mg of Procardia XL, the dose is increased to 60 mg Procardia given once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ST266 Versus Standard Care In Treating Partial Thickness Burns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* A signed IRB (Institutional Review Board)- approved Informed Consent Form;~* 18 - 65 years of age;~* Two (2) similar, non-contiguous, partial-thickness burn wounds between 50 cm2 and 250 cm2 in area with blisters removed in a Total Body Surface Area(TBSA) burn of less than or equal to 40% TBSA;~* Burns must be thermal burns of flame or scald etiology;~* Patient must present to the burn center within 8 hours of injury;~* Normal creatinine and bilirubin levels;~* If capable of bearing children, patient must be using a medically accepted means of birth control and have a negative serum pregnancy test;~* Willing to participate in the clinical study and comply with the requirements of the trial.~Exclusion Criteria:~* The two (2) chosen wounds must not be full-thickness (extending through the dermis into the subcutaneous tissue);~* Thermal burn from chemical, electrical or radiation causes;~* Neither the study wound nor the comparator wound can be \< 50 cm2 or \>250 cm2 in size and cannot be on the face or hands;~* Patients with significant pulmonary injury, i.e., smoke inhalation injury requiring ventilator support;~* Patients with diabetes;~* Patients with any immune deficiency including current treatment with corticosteroid medication, chemotherapeutic agents, anti-viral therapy, or concurrent radiation therapy within 30 days of signing the informed consent;~* Abnormal bilirubin, liver function studies (i.e., Alanine transaminase (ALT); Aspartate transaminase (AST)\> 2.0 times normal);~* Abnormal serum creatinine, receiving hemodialysis or peritoneal dialysis;~* Active cancer or a history of cancer in the 5 years prior to signing the informed consent form (history of basal cell carcinoma is allowed);~* Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to patient compliance;~* History of non-compliance with treatment or clinical visit attendance.~* Patients whose burns were previously treated with anything other than ice, cold water or dry dressing.~* Participation in an investigational trial within 30 days of study entry.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ST266 1 (Type: EXPERIMENTAL): Topical treatment every other day
- ST266 2 (Type: EXPERIMENTAL): Topical treatment every 4th day
- ST266 3 (Type: EXPERIMENTAL): Topical treatment every 7th day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Early Endoscopic Ultrasound - Based Sphincterotomy or Conservative Treatment in Severe Biliary Pancreatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria :~* age \> 18~* predicted severe acute biliary pancreatitis (including age \> 80, BMI \>30, pre-existing organ failure, Modified Glasgow score \> 3)~* timespan between onset and randomization \< 48 hrs~* informed consent signed by patient or liable person in case of emergency~Exclusion criteria :~* non biliary pancreatitis~* non severe pancreatitis~* age \< 18~* timespan between onset and randomization \> 48 hrs~* absence of consent~* ongoing pregnancy~* no social security insurance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- groupe 1 (Type: EXPERIMENTAL): Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
- Groupe 2 (Type: ACTIVE_COMPARATOR): usual procedure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues